Livestream: Addressing Barriers in Advancing Equitable Biomarker Testing in Community Oncology

Statement of Need

Biomarker or molecular testing to help oncologists match patients with the best cancer treatment can be challenging in the community oncology setting and for patients in underserved communities. At present, patients with cancer in racial or ethnic underserved communities are not getting biomarker testing at the same rate as White patients. Barriers to testing include insurance restrictions, conflicting guidelines, and community oncologists relying on the use of single-gene testing instead of multi-gene panels used more often by academic oncologists. In the multidisciplinary setting of community oncology, healthcare professionals (HCPs) would benefit from education on best practice models that provide cost-effective molecular testing services for the undertested underserved population, especially given that more recently U.S. Food and Drug Administration (FDA)-approved treatments require biomarker testing.

In this CME Outfitters livestream symposium expert faculty will evaluate the latest biomarker testing strategies in prostrate, bladder, and lung cancer, discussing how to integrate all members of the interdisciplinary care team in community oncology settings, identifying root causes of health inequity in cancer care and how to incorporate strategies to address unconscious bias and provide the latest biomarker testing services in cancer care management.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

Evaluate the latest biomarker testing strategies in prostate, bladder, and lung cancer, including their impact on treatment decision-making
Integrate all members of the care team in strategies to provide equitable biomarker testing in community oncology settings
Identify the root causes of health inequity in cancer care
Incorporate action-oriented strategies to address unconscious bias and patient social determinants of health (SDoH) in cancer care management

Financial Support

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Target Audience

Managed care physicians and pharmacists, community oncologists, oncology physician associates (PAs) and nurse practitioners (NPs), oncology nurses, and oncology pharmacists.

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 1.5

CME Outfitters, LLC, designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists (ACPE) 1.5

This application-based activity is approved for 1.50 contact hours (0.15 CEUs) of continuing pharmacy credit (JA0007185-0000-24-101-L01-P).

Nurses (ANCC) 1.5

This activity is designated for 1.50 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

Interprofessional (IPCE) 1.5

This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education Credit for learning and change.

Physician Assistants (AAPA): 1.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Brixner reports the following financial relationships:

Advisory Board: Bayer and Jazz Pharmaceuticals, Inc.

Consultant: LEO Pharma; Millcrreek Outcomes Group, LLC; Sanofi; and Tandem Therapeutics

Grants: Dexcom, Inc.

Ms. Donaldson reports no financial relationships to disclose.

Dr. Rivers reports the following financial relationships:

Stock Shareholder (ownership interest): Tempus AI, Inc.

Employment: Tempus AI, Inc.

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Andrea Edwards, PA-C (Peer Reviewer)
Mary Gleason, PhD, CHCP (Planning Committee)
Nichole Lainhart (Planning Committee)
David Modrak, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

MMS-149-101624-90

Livestream: Addressing Barriers in Advancing Equitable Biomarker Testing in Community Oncology

Faculty

Statement of Need

Learning Objectives

Financial Support

Target Audience